News

Public · Published

Alnylam Pharmaceuticals Price Target Cut to $240.00/Share From $300.00 by Morgan Stanley

Morgan Stanley cut its price target on Alnylam Pharmaceuticals to $240.00 per share from $300.00, while keeping an Equal-Weight rating on the stock.

Published:

Updated:

What happened

Morgan Stanley cut its price target on Alnylam Pharmaceuticals to $240.00 per share from $300.00, while keeping an Equal-Weight rating on the stock.

Confirmed

Global impact / market context

A lower price target means Morgan Stanley expects less upside for the stock than before, which can make some investors trim positions or demand stronger future results. The unchanged Equal-Weight rating suggests the firm is not negative, just less optimistic on value.

Analyst inference

Analyst price targets feed directly into how investors judge whether a stock looks cheap or expensive. A cut at a large bank can push holders to reassess their expected returns, potentially reducing buying interest until new company results confirm the outlook.

Analyst inference

What to watch

  1. Watch whether other analysts follow Morgan Stanley in lowering their price targets for Alnylam Pharmaceuticals, which would signal a broader shift in expectations rather than one firm's view. Confirmed
  2. Watch for company updates on drug sales and pipeline progress, because a price target cut without a formal downgrade often invites debate about whether the lower target was too cautious. Proposed
  3. Watch the share price reaction, since a target cut from $300 to $240 may change investor positioning if holders reduce exposure while the Equal-Weight rating remains in place. Analyst inference

Evidence

  • Original source link unavailable